156 related articles for article (PubMed ID: 32493317)
21. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
22. Carcinoma arising in a proliferating trichilemmal cyst expresses fetal and trichilemmal hair phenotype.
Haas N; Audring H; Sterry W
Am J Dermatopathol; 2002 Aug; 24(4):340-4. PubMed ID: 12142616
[TBL] [Abstract][Full Text] [Related]
23. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
24. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival.
Amit M; Tam S; Abdelmeguid AS; Roberts DB; Takahashi Y; Raza SM; Su SY; Kupferman ME; DeMonte F; Hanna EY
Br J Cancer; 2017 Jun; 116(12):1564-1571. PubMed ID: 28494469
[TBL] [Abstract][Full Text] [Related]
25. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
26. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
[TBL] [Abstract][Full Text] [Related]
27. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
[TBL] [Abstract][Full Text] [Related]
28. The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia.
Rinonce HT; Sastri DJ; Trisnawati F; Kameswari B; Ferronika P; Irianiwati
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1454. PubMed ID: 34110110
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
[TBL] [Abstract][Full Text] [Related]
30. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
31. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
32. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
33. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract][Full Text] [Related]
34. Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma.
Zilberg C; Lee MW; Yu B; Ashford B; Kraitsek S; Ranson M; Shannon K; Cowley M; Iyer NG; Palme CE; Ch'ng S; Low TH; O'Toole S; Clark JR; Gupta R
Mod Pathol; 2018 Feb; 31(2):275-287. PubMed ID: 28984303
[TBL] [Abstract][Full Text] [Related]
35. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis and clinical correlation of metastatic colorectal cancer.
Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
[TBL] [Abstract][Full Text] [Related]
37. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.
McCart Reed AE; Kalaw E; Nones K; Bettington M; Lim M; Bennett J; Johnstone K; Kutasovic JR; Saunus JM; Kazakoff S; Xu Q; Wood S; Holmes O; Leonard C; Reid LE; Black D; Niland C; Ferguson K; Gresshoff I; Raghavendra A; Harvey K; Cooper C; Liu C; Kalinowski L; Reid AS; Davidson M; Pearson JV; Pathmanathan N; Tse G; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox SB; O'Toole SA; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2019 Feb; 247(2):214-227. PubMed ID: 30350370
[TBL] [Abstract][Full Text] [Related]
38. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
39. Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma.
Howitt BE; Jia Y; Sholl LM; Barletta JA
Thyroid; 2013 Oct; 23(10):1256-62. PubMed ID: 23477374
[TBL] [Abstract][Full Text] [Related]
40. Mutational spectrum of conserved regions of TP53 and PTEN genes in Kangri cancer (of the skin) in the Kashmiri population.
Hussain I; ul Rehman S; Afroze D; Zahoor L; Abdullah S; Hafiz A; Shah ZA; Iqbal S; Shaffi M; Das BC; Siddiqi MA
Mutat Res; 2009 May; 676(1-2):5-10. PubMed ID: 19486858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
